These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2750360)

  • 1. [Testing the immunity to orthopoxviruses in the white mouse with vaccinia virus].
    Czerny CP; Mahnel H; Hornstein O
    Zentralbl Veterinarmed B; 1989 Mar; 36(2):100-12. PubMed ID: 2750360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
    Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
    Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
    Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
    J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y; Kosugi A; Yoshioka T; Tomita S; Fujiwara H; Hamaoka T
    J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection.
    Tanaka-Kataoka M; Kunikata T; Takayama S; Iwaki K; Ohashi K; Ikeda M; Kurimoto M
    Cytokine; 1999 Aug; 11(8):593-9. PubMed ID: 10433806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
    Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
    J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response.
    Brandt T; Heck MC; Vijaysri S; Jentarra GM; Cameron JM; Jacobs BL
    Virology; 2005 Mar; 333(2):263-70. PubMed ID: 15721360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells.
    Ueda S; Wakamiya N; Wu KS; Kato S; Fujiwara H; Hamaoka T
    Biken J; 1984 Mar; 27(1):1-7. PubMed ID: 6385960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression.
    Flexner C; Hügin A; Moss B
    Nature; 1987 Nov 19-25; 330(6145):259-62. PubMed ID: 3118219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
    Morrison LA; Knipe DM
    Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with a recombinant fowlpox virus expressing a hepatitis C virus core-E1 polyprotein variant, protects mice and African green monkeys (Chlorocebus aethiops sabaeus) against challenge with a surrogate vaccinia virus.
    Alvarez-Lajonchere L; Amador-Cañizares Y; Frías R; Milian Y; Musacchio A; Guerra I; Acosta-Rivero N; Martínez G; Castro J; Puentes P; Cosme K; Dueñas-Carrera S
    Biotechnol Appl Biochem; 2008 Oct; 51(Pt 2):97-105. PubMed ID: 18215116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
    Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
    Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active and passive immunization against oral Candida albicans infection in a murine model.
    Farah CS; Ashman RB
    Oral Microbiol Immunol; 2005 Dec; 20(6):376-81. PubMed ID: 16238599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of mucosal immunity in herpes simplex virus infection.
    Kuklin NA; Daheshia M; Chun S; Rouse BT
    J Immunol; 1998 Jun; 160(12):5998-6003. PubMed ID: 9637514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection.
    Pope M; Chung SW; Mosmann T; Leibowitz JL; Gorczynski RM; Levy GA
    J Immunol; 1996 May; 156(9):3342-9. PubMed ID: 8617959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
    Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
    Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.